×

Arog Pharmaceuticals Announces Abstracts to be Presented at the 2015 American Society of Hematology Annual Meeting (ASH)

DALLAS, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced the upcoming presentation of four abstracts at the 57th American Society of Hematology (ASH) annual meeting. The conference will take place December 5-8 in Orlando, Florida. Details for the presentation are provided below.

Abstract #2468

Title: Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Authors: Haijiao Zhang, Kevin Matthew Watanabe-Smith, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Hagop M. Kantarjian, Judy Ho, Jeremy Davis, Blake Pond, Gautam Borthakur, Abhijit Ramachandran, Jorge E. Cortes, Robert Collins, and Jeffrey W. Tyner

Presenter: Haijiao Zhang
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
Date: Sunday, December 6, 2015
Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall A

Abstract #3695

Title: Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

Authors: John Carl Panetta, Sharyn D Baker, Hagop M. Kantarjian, Clinton Stewart, Blake Pond, Meghan Macaraeg, Tolu Makinde, Sheetal Vali, Naval Daver, Abhijit Ramachandran, Robert Collins, and Jorge E. Cortes

Presenter: John Panetta
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
Date: Monday, December 7, 2015
Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall A

Abstract #676

Title: Azacitidine in Combination with the Selective FLT3 Kinase Inhibitor Crenolanib Effectively Disrupts Stromal Protection of CD34+ Leukemia-Initiating Cells (LIC) in FLT3-ITD+ Acute Myeloid Leukemia (AML)

Authors: Anne-Kathrin Garz, Stefan Habringer, Saskia Wolf, Binje Vick, Marie-Theresa Weickert, Irmela Jeremias, Karsten Spiekermann, Christian Peschel, Robert A.J. Oostendorp, Ulrich Keller, and Katharina S. Götze

Presenter: Anne-Kathrin Garz
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Acute Myeloid Leukemia: An Understanding of Molecular Mechanisms Guides Rational Drug Combinations
Date: Monday, December 7, 2015
Time: 2:45 PM – 4:15 PM EST
Location: Orange County Convention Center, W307

Abstract #4359

Title: Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell TransplantClinically Relevant Abstract

Authors: Robert Collins, Hagop M. Kantarjian, Farhad Ravandi, Jenny Chen, Meghan Macaraeg, Vinoo Urity, Blake Pond, Abhijit Ramachandran, and Jorge E. Cortes

Presenter: Robert Collins
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
Date: Monday, December 7, 2015
Time: 6:00 PM – 8:00 PM EST
Location: Orange County Convention Center, Hall A

About Arog Pharmaceuticals, Inc.

Arog Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I kinase inhibitors. Arog is poised to enroll patients in pivotal, randomized Phase III trials of its lead molecule, crenolanib. In addition to the four clinical trials it has already completed, Arog is also engaged in three ongoing Phase II clinical trials. For more information, please visit the company's website, http://www.arogpharma.com.

About Crenolanib

Arog's lead molecule, crenolanib, is currently being clinically investigated as a treatment for multiple cancers, including acute myeloid leukemia (AML), gastrointestinal stromal tumors (GIST), glioma, and non-small cell lung cancer (NSCLC). It is an orally bioavailable benzimidazole type I kinase inhibitor that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases FLT3 and PDGFRα/β. This molecule has an established record of patient safety and has been used to treat over 250 patients from around the world.

About FLT3

FLT-3 is a class III receptor tyrosine kinase, and its signaling is considered important for the normal development of hematopoietic stem cells and progenitor cells. The FLT-3 gene is one of the most frequently mutated genes (~35%) in acute myeloid leukemia (AML). One such mutation, internal tandem duplications of FLT-3 (FLT3-ITD), is a prognostic indicator associated with adverse disease outcome.

About PDGFRα/β

Platelet-derived growth factor receptors (PDGFR) α and β are cell surface tyrosine kinase receptors and are important factors regulating cell proliferation and cell development, as well as several diseases, including cancers like brain tumors and sarcomas. In clinical tests, crenolanib has been shown to inhibit both PDGFR α and β phosphorylation, thus preventing downstream signaling.

CONTACT: The Trout Group Peter Rahmer (646) 378-2973 prahmer@troutgroup.comSource:Arog Pharmaceuticals, Inc.